Titan Bio-Tech (TITANBIO) | Financial Analysis & Statements
Titan Bio-Tech Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
565.1M
Gross Profit
291.4M
51.57%
Operating Income
95.6M
16.92%
Net Income
85.3M
15.09%
EPS (Diluted)
₹2.06
Balance Sheet Metrics
Total Assets
1.7B
Total Liabilities
213.0M
Shareholders Equity
1.5B
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
45.6M
Free Cash Flow
12.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Titan Bio-Tech Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.6B | 1.6B | 1.4B | 1.2B | 1.4B |
| Cost of Goods Sold | 892.5M | 937.4M | 856.4M | 705.3M | 752.8M |
| Gross Profit | 672.0M | 703.4M | 583.6M | 530.2M | 669.5M |
| Gross Margin % | 43.0% | 42.9% | 40.5% | 42.9% | 47.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 139.5M | 111.6M | 96.4M | 65.7M | 55.8M |
| Other Operating Expenses | 9.9M | 8.4M | 9.1M | 9.4M | 5.9M |
| Total Operating Expenses | 149.5M | 120.0M | 105.5M | 75.1M | 61.7M |
| Operating Income | 212.6M | 309.5M | 270.0M | 289.0M | 443.7M |
| Operating Margin % | 13.6% | 18.9% | 18.7% | 23.4% | 31.2% |
| Non-Operating Items | |||||
| Interest Income | 5.1M | 857.0K | 443.0K | 1.1M | 573.2K |
| Interest Expense | 5.9M | 9.4M | 5.6M | 6.9M | 14.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 243.7M | 315.3M | 281.2M | 289.7M | 427.1M |
| Income Tax | 61.0M | 78.7M | 70.9M | 72.8M | 110.0M |
| Effective Tax Rate % | 25.0% | 24.9% | 25.2% | 25.1% | 25.8% |
| Net Income | 215.3M | 248.5M | 248.4M | 216.8M | 317.1M |
| Net Margin % | 13.8% | 15.1% | 17.3% | 17.6% | 22.3% |
| Key Metrics | |||||
| EBITDA | 285.6M | 352.4M | 313.1M | 320.3M | 471.3M |
| EPS (Basic) | ₹5.21 | ₹30.07 | ₹30.06 | ₹26.24 | ₹36.71 |
| EPS (Diluted) | ₹5.21 | ₹30.07 | ₹30.06 | ₹26.24 | ₹36.71 |
| Basic Shares Outstanding | 41318500 | 8263700 | 8263700 | 8263834 | 8263700 |
| Diluted Shares Outstanding | 41318500 | 8263700 | 8263700 | 8263834 | 8263700 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Titan Bio-Tech Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 51.3M | 28.4M | 48.6M | 68.1M | 54.5M |
| Short-term Investments | 4.3M | - | - | - | 1.8M |
| Accounts Receivable | 188.2M | 186.6M | 210.1M | 163.6M | 181.0M |
| Inventory | 508.2M | 458.8M | 365.6M | 346.8M | 325.4M |
| Other Current Assets | 38.7M | 50.5M | 43.2M | 59.0M | 27.3M |
| Total Current Assets | 790.4M | 721.7M | 683.1M | 637.6M | 588.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 571.6M | 519.4M | 22.9M | 348.8M | 335.1M |
| Goodwill | 1.2M | 950.0K | 852.0K | 1.0M | 917.3K |
| Intangible Assets | 1.2M | 950.0K | 852.0K | 1.0M | 917.3K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | 1.0K | 1.1M | - |
| Total Non-Current Assets | 956.7M | 844.1M | 662.1M | 443.4M | 418.9M |
| Total Assets | 1.7B | 1.6B | 1.3B | 1.1B | 1.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 52.2M | 33.7M | 55.5M | 41.6M | 37.1M |
| Short-term Debt | 23.8M | 71.6M | 70.8M | 67.4M | 85.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 32.7M | 23.9M | 24.3M | 17.5M | 17.9M |
| Total Current Liabilities | 177.4M | 191.3M | 203.5M | 169.5M | 192.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 4.2M | 11.5M | 14.3M | 21.9M | 62.5M |
| Deferred Tax Liabilities | 15.2M | 13.7M | 12.1M | 12.8M | 13.9M |
| Other Non-Current Liabilities | - | 100.0M | 1.0K | 0 | - |
| Total Non-Current Liabilities | 35.7M | 140.0M | 42.5M | 49.0M | 89.6M |
| Total Liabilities | 213.0M | 331.3M | 246.0M | 218.5M | 282.4M |
| Equity | |||||
| Common Stock | 82.6M | 82.6M | 82.6M | 82.6M | 82.6M |
| Retained Earnings | 1.4B | 1.2B | 928.2M | 759.9M | 517.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.5B | 1.3B | 1.1B | 862.4M | 724.8M |
| Key Metrics | |||||
| Total Debt | 28.0M | 83.0M | 85.1M | 89.3M | 147.9M |
| Working Capital | 613.0M | 530.5M | 479.6M | 468.1M | 395.5M |
Balance Sheet Composition
Titan Bio-Tech Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 243.7M | 315.3M | 281.2M | 289.7M | 427.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -53.9M | -51.0M | -43.5M | -58.2M | -184.1M |
| Operating Cash Flow | 197.8M | 276.0M | 245.1M | 240.2M | 259.6M |
| Investing Activities | |||||
| Capital Expenditures | -85.3M | -86.7M | -131.6M | -136.8M | -48.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -13.2M | -116.0M | -75.6M | -27.6M | - |
| Investment Sales | 150.0K | - | - | - | - |
| Investing Cash Flow | -98.3M | -202.7M | -207.2M | -164.4M | -48.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -16.5M | -14.9M | -12.4M | -12.4M | -8.3M |
| Debt Issuance | - | 1.5M | - | 27.3M | - |
| Debt Repayment | -2.7M | - | -7.8M | -7.5M | -97.5M |
| Financing Cash Flow | -67.2M | -13.2M | -17.7M | 110.4M | -105.8M |
| Free Cash Flow | 106.8M | 14.6M | 77.1M | 83.6M | 142.2M |
| Net Change in Cash | 32.3M | 60.2M | 20.2M | 186.2M | 105.2M |
Cash Flow Trend
Titan Bio-Tech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
74.64
Price to Book
12.19
Price to Sales
10.54
PEG Ratio
-1.22
Profitability Ratios
Profit Margin
14.13%
Operating Margin
16.92%
Return on Equity
14.04%
Return on Assets
12.32%
Financial Health
Current Ratio
2.78
Debt to Equity
5.32
Beta
-0.48
Per Share Data
EPS (TTM)
₹6.58
Book Value per Share
₹40.29
Revenue per Share
₹46.59
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TITANBIO | 19.9B | 74.64 | 12.19 | 14.04% | 14.13% | 5.32 |
| Biocon | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
| Dishman Carbogen | 26.5B | 22.30 | 0.42 | 0.06% | 4.25% | 40.20 |
| Panacea Biotec | 21.8B | 182.62 | 2.65 | -1.01% | -1.29% | 2.79 |
Financial data is updated regularly. All figures are in the company's reporting currency.





